

# Bart J A Rijnders

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8781424/bart-j-a-rijnders-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76  
papers

5,556  
citations

27  
h-index

74  
g-index

85  
ext. papers

7,295  
ext. citations

9  
avg, IF

5.42  
L-index

#	Paper	IF	Citations
76	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2147331	10.4	4
75	Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2147375	10.4	6
74	Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients.. <i>Science Immunology</i> , <b>2022</b> , 7, eabo2202	28	48
73	Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning.. <i>Nature Communications</i> , <b>2022</b> , 13, 915	17.4	4
72	Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients.. <i>Nature Communications</i> , <b>2022</b> , 13, 2583	17.4	0
71	Incidence of HCV Reinfection Among HIV-Positive MSM and Its Association With Sexual Risk Behavior: A Longitudinal Analysis. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 460-467	11.6	9
70	Interferon- $\gamma$ Auto-antibodies in Convalescent Plasma Therapy for COVID-19. <i>Journal of Clinical Immunology</i> , <b>2021</b> , 1	5.7	5
69	Influenza-Associated Pulmonary Aspergillosis: Seek, and You Shall Find!. <i>Critical Care Medicine</i> , <b>2021</b> , 49, e1265-e1266	1.4	3
68	Multinational Observational Cohort Study of COVID-19-Associated Pulmonary Aspergillosis. <i>Emerging Infectious Diseases</i> , <b>2021</b> , 27, 2892-2898	10.2	19
67	Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. <i>Nature Communications</i> , <b>2021</b> , 12, 3189	17.4	76
66	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. <i>Intensive Care Medicine</i> , <b>2021</b> , 47, 674-686	14.5	18
65	Significant impact of COVID-19 on HIV care in hospitals affecting the first pillar of the HIV care continuum. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	3
64	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , <b>2021</b> , 47, 819-834	14.5	30
63	SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 2020-2028	7	16
62	in Critically Ill COVID-19 Patients: A Scoping Review. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	8
61	Effects of treatment of COVID-19 with convalescent plasma in 25 B-cell depleted patients. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	9
60	Frequency of Positive Tests in COVID-19 Patients in Comparison to Other Patients with Pulmonary Infections Admitted to the Intensive Care Unit. <i>Journal of Clinical Microbiology</i> , <b>2021</b> , 59,	9.7	8

59	HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study. <i>Lancet HIV,the</i> , <b>2021</b> , 8, e96-e105	7.8	12
58	A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation. <i>Microorganisms</i> , <b>2021</b> , 9,	4.9	3
57	Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 1234-1241	5.1	3
56	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003101	11.6	8
55	Epidemiology of Pneumonia and (Non-)use of Prophylaxis. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2020</b> , 10, 224	5.9	8
54	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 1524-1535	14.5	149
53	Paradoxal Trends in Azole-Resistant <i>Aspergillus fumigatus</i> in a National Multicenter Surveillance Program, the Netherlands, 2013-2018. <i>Emerging Infectious Diseases</i> , <b>2020</b> , 26, 1447-1455	10.2	26
52	An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. <i>Nature Communications</i> , <b>2020</b> , 11, 3436	17.4	224
51	Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWP-EBMT, EORTC-IDG and SEIFEM survey. <i>Mycoses</i> , <b>2020</b> , 63, 420-429	5.2	2
50	Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B. <i>Medical Mycology</i> , <b>2020</b> , 58, 874-880	3.9	4
49	High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections. <i>Mycoses</i> , <b>2020</b> , 63, 122-130	5.2	27
48	<i>Madurella mycetomatis</i> , the main causative agent of eumycetoma, is highly susceptible to olorofim. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 936-941	5.1	17
47	Persistent candida arthritis successfully treated with micafungin instillation and surgery. A case report. <i>Medical Mycology Case Reports</i> , <b>2020</b> , 27, 29-31	1.7	
46	Point of care aspergillus testing in intensive care patients. <i>Critical Care</i> , <b>2020</b> , 24, 642	10.8	10
45	Influenza Coinfection: Be(a)ware of Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 349-350	11.6	11
44	Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. <i>Medical Mycology</i> , <b>2020</b> , 58, 444-452	3.9	38
43	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study <b>2020</b> , 17, e1003101		
42	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study <b>2020</b> , 17, e1003101		

41	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study <b>2020</b> , 17, e1003101		
40	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study <b>2020</b> , 17, e1003101		
39	Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210179	3.7	23
38	Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, S244-S259	11.6	26
37	Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, S260-S274	11.6	35
36	Influenza and Invasive Aspergillosis in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 2037	11.6	4
35	Is HIV-1 viraemia below 20 copies/mL in antiretroviral-treated patients associated with virologic outcome?. <i>Infectious Diseases</i> , <b>2019</b> , 51, 259-267	3.1	4
34	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz330	1	16
33	Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy. <i>EClinicalMedicine</i> , <b>2019</b> , 17, 100210	11.3	10
32	Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 269-277	18.8	25
31	Diagnosing Invasive Pulmonary Aspergillosis in Hematology Patients: a Retrospective Multicenter Evaluation of a Novel Lateral Flow Device. <i>Journal of Clinical Microbiology</i> , <b>2019</b> , 57,	9.7	14
30	Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 1463-1471	11.6	105
29	High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 1352-1359	11.6	37
28	The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 698-706	7	24
27	The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol. <i>Mycoses</i> , <b>2018</b> , 61, 656-664	5.2	17
26	HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 688-697	7	44
25	Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 782-792	35.1	379
24	Reply to Darcis and Berkhout. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 2020-2021	7	

23	Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. <i>Current Opinion in Infectious Diseases</i> , <b>2018</b> , 31, 471-480	5.4	86
22	Acute hepatitis C in HIV-negative men who have sex with men in the Netherlands and Belgium: a call for action. <i>Sexually Transmitted Infections</i> , <b>2018</b> , 94, 297	2.8	4
21	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. <i>Lancet HIV,the</i> , <b>2017</b> , 4, e195-e204	7.8	53
20	Influenza-Associated Aspergillosis in Critically Ill Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 524-527	10.2	127
19	Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. <i>Lancet HIV,the</i> , <b>2017</b> , 4, e547-e554	7.8	73
18	Echinocandin to fluconazole step-down therapy in critically ill patients with invasive, susceptible <i>Candida albicans</i> infections. <i>Mycoses</i> , <b>2016</b> , 59, 179-85	5.2	10
17	Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1632-6	5.1	23
16	Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 807-12	13.4	22
15	Frequencies of Circulating MAIT Cells Are Diminished in Chronic HCV, HIV and HCV/HIV Co-Infection and Do Not Recover during Therapy. <i>PLoS ONE</i> , <b>2016</b> , 11, e0159243	3.7	45
14	Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. <i>Lancet Infectious Diseases, The</i> , <b>2016</b> , 16, 1423-1429	25.5	63
13	Evidence gathered from randomized clinical trials and observational studies on the equivalence of emtricitabine and Lamivudine. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 1732-3	11.6	4
12	Validation of a new <i>Aspergillus</i> real-time PCR assay for direct detection of <i>Aspergillus</i> and azole resistance of <i>Aspergillus fumigatus</i> on bronchoalveolar lavage fluid. <i>Journal of Clinical Microbiology</i> , <b>2015</b> , 53, 868-74	9.7	114
11	Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life. <i>International Journal of Antimicrobial Agents</i> , <b>2015</b> , 46, 82-7	14.3	15
10	Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control Study. <i>Open Forum Infectious Diseases</i> , <b>2015</b> , 2, ofv115	1	64
9	Aspergillosis due to voriconazole highly resistant <i>Aspergillus fumigatus</i> and recovery of genetically related resistant isolates from domiciles. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 513-20	11.6	248
8	Clinical implications of azole resistance in <i>Aspergillus fumigatus</i> , The Netherlands, 2007-2009. <i>Emerging Infectious Diseases</i> , <b>2011</b> , 17, 1846-54	10.2	326
7	Prevention of catheter-related bacteremia with a daily ethanol lock in patients with tunneled catheters: a randomized, placebo-controlled trial. <i>PLoS ONE</i> , <b>2010</b> , 5, e10840	3.7	230
6	Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 1-45	11.6	2312

5	Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2008</b> , 21, 855-9	3.5	27
4	Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 47, 1507-12	11.6	77
3	Use of semiautomatic treatment advice to improve compliance with Infectious Diseases Society of America guidelines for treatment of intravascular catheter-related infection: a before-after study. <i>Clinical Infectious Diseases</i> , <b>2003</b> , 37, 980-3	11.6	7
2	Effects of Potent Neutralizing Antibodies from Convalescent Plasma in Patients Hospitalized for Severe SARS-CoV-2 Infection.		3
1	SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model		16